4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in 4D Molecular Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 121
- −5 vs. Q1 2025
- Shares held
- 40.4M
- −2.69M (−6.2%) vs. Q1 2025
- Total value
- $149.9M
- +$10.0M (+7.2%) vs. Q1 2025
- New holders
- 17
- 43 more added
- Sold out
- 22
- 40 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FDMT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 157 | $771.2M |
| Q1 2026 | 153 | $471.4M |
| Q4 2025 | 153 | $400.5M |
| Q3 2025 | 134 | $343.2M |
| Q2 2025 | 121 | $149.9M |
| Q1 2025 | 126 | $139.8M |
| Q4 2024 | 146 | $260.6M |
| Q3 2024 | 140 | $629.2M |
| Q2 2024 | 143 | $1.20B |
| Q1 2024 | 147 | $1.79B |
| Q4 2023 | 111 | $859.8M |
| Q3 2023 | 110 | $533.6M |
| Q2 2023 | 100 | $745.3M |
| Q1 2023 | 94 | $522.3M |
| Q4 2022 | 96 | $621.9M |
| Q3 2022 | 88 | $210.4M |
| Q2 2022 | 90 | $181.7M |
| Q1 2022 | 80 | $395.3M |
| Q4 2021 | 77 | $541.8M |
| Q3 2021 | 63 | $515.1M |
| Q2 2021 | 56 | $400.0M |
| Q1 2021 | 64 | $664.8M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding 4D Molecular Therapeutics, Inc.; share changes are against Q1 2025.